[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BarnyardBull72 Avatar @BarnyardBull72 David

David posts on X about $lexx, $nvo, $lly, guess the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks finance countries

Social topic influence $lexx #1, $nvo #118, $lly #80, guess, dyor #174, ceo, $pfe, $abbv #18, eli lilly #112, billions

Top accounts mentioned or mentioned by @grok @lexariabiocorp @novonordiskus @elilillyandco @wa7ermelon @zeffpena @pfizer @shadowofezra @generalmcnews @wind4me @plugpowerinc @merck @whitehouse @presssec @timonpoint @themagahulk @senmikelee @mattwallace888 @tommysantos14 @kobeissiletter

Top assets mentioned Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) AbbVie Inc (ABBV) Bitcoin Incognito (XBI) Viking Therapeutics, Inc (VKTX)

Top Social Posts

Top posts by engagements in the last XX hours

"$LEXX Reminder 💡. We are in the quiet period before the readout of Lexarias much anticipated human trial GLP1 results. Readout has been guided to be announced before end of Q4 which means IMMINENT. My guess is this week or next as anytime after that is into the holidays 🎄. Interim data released last summer was 🔥. Lets hope final meets or beats interim. DYOR"
X Link 2025-12-10T16:30Z XXX followers, 1064 engagements

"$LEXX This is the one biotech everyone will chase at $10+ after pretending they knew all along. Facts: 🚀 First real solution to GLP-1 nausea 🚀 Oral delivery WITHOUT gut damage 🚀 Faster uptake 🚀 Massive human data readout IMMINENT 🚀 Multiple pharma already circling behind the scenes 🚀 Micro float explosive setup This isnt a meme stock. This is a platform technology worth billions still sitting under $X because the market is brain-dead short term. They delay. I accumulate. They doubt. I prepare. When this detonates it wont be a gentle climb. Itll be limit up violence. WINTER OF GLP-1 ="
X Link 2025-10-24T03:29Z XXX followers, 1108 engagements

"$LEXX $LLY Eli Lilly just confirmed it the war for oral GLP-1 has begun. 💊🔥 Theyre stockpiling billions of weight-loss pills before FDA approval. Heres the truth nobody will say out loud: ✅ Oral GLP-1 wont scale globally without a delivery breakthrough ✅ Bioavailability + tolerability are the choke points ✅ Lexaria $LEXX already showed zero nausea in human GLP-1 data ✅ Pharma cant win this war without better delivery tech This isnt about a drug anymore. Its about the platform that controls the pill. Lexaria holds that position. Pharma knows it. BD firm hired. Silence is now strategy. The"
X Link 2025-10-28T12:44Z XXX followers, 1366 engagements

"🥵🥵🥵 $LEXX Meanwhile $NVO CEO just said theyre bringing in assets from elsewhere to complement what we already have. $LEXX DehydraTECH already slashed GI events XXXX% vs Rybelsus. Topline drops any day. Theyre shopping for oral fixes. Were holding the receipt. 🧾🔥"
X Link 2025-11-06T15:04Z XXX followers, XXX engagements

"🚨 $LEXX Thread: The real tell in $LEXX GLP-1 trial 👀 Everyones debating who Lexarias mystery partner is $NVO $PFE or $LLY Heres your smoking-barrel clue: 💊 The trial includes Rybelsus (oral semaglutide) as a positive control arm. Thats Novo Nordisks proprietary branded tablet not a generic semaglutide. You dont structure human dosing arms around a competitors IP unless: X Youve got explicit alignment or licensing clearance. X Youre designing data for that IP owners regulatory or LCM program. Add it up: Rybelsus control arm ✅ Identical titration schedule to Novos OASIS-1 ✅ Same metabolic +"
X Link 2025-11-06T21:35Z XXX followers, 1228 engagements

"Fair take but this is exactly why the future of oral GLP-1s isnt in small-molecule chemistry. Its in advanced delivery tech. DehydraTECH from $LEXX already demonstrated it can amplify bioavailability while using less drug less liver load and faster onset. Thats the answer to megadosing risk. The winners wont be those making new molecules itll be those who make the existing ones work better"
X Link 2025-11-07T14:34Z XXX followers, XXX engagements

"🚨 Vanguard doubles down on $LEXX Just dropped: Vanguard Group boosted its Lexaria ($LEXX) position by +93.8% in the latest 13F. ✅ Flow magnitude: For a microcap like $LEXX even a $250K incremental buy matters. Vanguard funds are risk-constrained so taking any active risk in a sub-$100M company means they expect binary upside. 🚀"
X Link 2025-11-08T19:07Z XXX followers, XXX engagements

"$NVO just posted ANOTHER new Alzheimers role this time in APAC. $LEXX is the 🔑 ➡ Global build-out for semaglutide Alzheimers program is accelerating fast. ➡ Medical & Marketing = pre-launch infrastructure not R&D. Now ask yourself if sema shows cognitive benefit in EVOKE how do you make it oral brain-penetrant and tolerable for mass-market use 🤔 $LEXX 🔥 Theres only one small-cap already proving that tech works: $LEXX"
X Link 2025-11-11T18:50Z XXX followers, XXX engagements

"$LEXX 🤭 👇. Quote in press release. Discussions with PharmaCOs human clinical development team. 💣 Translation: THEYRE NOT TALKING TRIALS. THEYRE TALKING TAKEOVER. BUYOUT MODE ACTIVATED FULL DATA FIRST CLINICAL TEAM IN THE ROOM who is the mystery pharma Your best guess $NVO $LLY $PFE"
X Link 2025-11-12T15:44Z XXX followers, XXX engagements

"Aggressive M&A strategy. 👀 $LEXX 👀 Could $NVO be the mystery pharma partner behind the MTA"
X Link 2025-11-13T14:23Z XXX followers, XXX engagements

"🎯 The $LEXX Buyout Thesis: The ONLY Game Left for Big Pharma 💊 The GLP-1 market is massive ($100B). The problem Side effects and injections. Lexaria has the solution: DehydraTECH. Their human trials show it's better than Novo Nordisk's SNAC tech (Rybelsus) for side effect reduction & absorption. Novo owns SNAC. $LEXX owns DehydraTECH. If their final data (imminent) mirrors strong interim results $LEXX is the ONLY clinically validated platform available for every other pharma giant (Lilly Pfizer etc.) to compete in the oral GLP-1 space. This is a scarcity play with massive upside potential."
X Link 2025-11-25T13:07Z XXX followers, 2276 engagements

"$ABBV standard of care differentiator ➡ $LEXX 👀"
X Link 2025-12-03T22:43Z XXX followers, XXX engagements

"$LEXX 👀 Novos seeing tiny brain signals but NO cognition winsclassic delivery fail. DehydraTECH crushes it with 3-7x BETTER brain penetration for semaglutide and superior absorption. Theyre desperate for a fix $LEXX is the scarcity play they cant ignore. MTA extension screams deal incoming post-Q4 readout IMO. 🚀💥 #GLP1 #Alzheimers #Biotech $NVO"
X Link 2025-12-04T14:06Z XXX followers, 1576 engagements

"$LEXX in addition to the below Lexaria currently has an MTA signed with a global pharma co ( $NVO $LLY $ABBV ). The MYA was extended to April 2026 which points to a partnership decision being made by the MTA holder by that timeframe. Lexaria also hired a BD firm this past fall. 🔥"
X Link 2025-12-10T16:40Z XXX followers, XXX engagements

"@eryney_ok BPC-157 only stimulates angiogenesis in damaged or inflamed tissue Not in: healthy tissue heart organs tumors systemic vasculature This is because BPC activates VEGF only when injury-derived signals are present and suppresses abnormal angiogenesis elsewhere"
X Link 2025-12-11T14:11Z XXX followers, XXX engagements